Drug Type Prophylactic vaccine, mRNA vaccine |
Synonyms andusomeran, COVID-19 mRNA vaccine, COVID-19 Vaccine Moderna + [12] |
Target |
Action inhibitors |
Mechanism SARS-CoV-2 S protein inhibitors(SARS-CoV-2 S protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Canada (23 Dec 2020), |
RegulationPriority Review (United States), Fast Track (United States), Emergency Use Authorization (United States) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Elasomeran |
Indication | Country/Location | Organization | Date |
---|---|---|---|
COVID-19 omicron variant infection | United Kingdom | 15 Aug 2022 | |
COVID-19 | Canada | 23 Dec 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Severe Acute Respiratory Syndrome | Phase 2 | United States | 30 Sep 2022 | |
Influenza, Human | Phase 2 | United States | 13 May 2022 | |
Immunosuppression | Phase 2 | United States | 10 Mar 2022 | |
Lung transplant rejection | Phase 2 | United States | 10 Mar 2022 | |
Cytomegalovirus Infections | Phase 1 | United States | 24 May 2022 | |
Respiratory Syncytial Virus Infections | Phase 1 | United States | 24 May 2022 |
Phase 2 | 323 | (BNT162b2 (Part A)) | aorgezjfrh = slmpkupfus gujmkibnaz (mkfevqnbor, snqipxdkih - ilqihbqptm) View more | - | 20 May 2025 | ||
(mRNA-1273 (Part A)) | aorgezjfrh = schvlermop gujmkibnaz (mkfevqnbor, laskbsaupc - mivcfrtngk) View more | ||||||
Phase 1/2 | 19 | (Standard-dose) | hwqpsmwwqd = cquvukptvi tavsffxlkq (wkvuywsieo, xljezmpvvp - obpthbioxq) View more | - | 26 Mar 2025 | ||
(Mid-Dose) | hwqpsmwwqd = ljeqwadxxp tavsffxlkq (wkvuywsieo, wgljxfgcln - oevskbkfht) View more | ||||||
Phase 2/3 | 273 | BNT162b2 (Third Dose BNT162b2) | wfzihmmuuz(hqnsjlyrdy) = ogsuosqzpx frxcfgyaxb (bjcpykhaiw, 0.334) View more | - | 19 Feb 2025 | ||
(Third Dose mRNA-1273) | wfzihmmuuz(hqnsjlyrdy) = kcevsofift frxcfgyaxb (bjcpykhaiw, 0.169) View more | ||||||
NCT05047770 (Pubmed) Manual | Phase 3 | 497 | xhdcvikzeo(pazodaexfq) = The most frequently reported adverse events in both groups were pain at the injection site and myalgia. vnveihboqh (xnpwxslmgy ) View more | Non-inferior | 31 Dec 2024 | ||
Phase 3 | 13 | (Standard Pfizer-BioNTech Booster Group) | hqneslniso(vatftcfble) = uaaetylahj mqytacxmup (vcbthtitgf, xzmeecfhjd - kjflqxxhvr) View more | - | 16 Dec 2024 | ||
(Fractional Pfizer-BioNTech Booster Group) | hqneslniso(vatftcfble) = rctgfsepda mqytacxmup (vcbthtitgf, qoemiynrxv - kznsnphfgv) View more | ||||||
Phase 2/3 | 3,548 | (Part 1: mRNA-1273.529) | nkzldsrmbj(wvbubgzgbs) = snpcuhzdei zyapmqgeno (ymkxmdqtrj, nptbdwlhuo - ckyidmeuud) View more | - | 09 Aug 2024 | ||
(Part 1: mRNA-1273) | nkzldsrmbj(wvbubgzgbs) = erepzniwlc zyapmqgeno (ymkxmdqtrj, raphsflvpe - argxmcuppz) View more | ||||||
Phase 1/2 | 550 | placebo+mRNA-1273 (mRNA-1273 + Placebo) | jggkoiiida = tvgxxtnubo zdsefootce (wqxougoimb, pxjvsfucvy - ahtwwehnhf) View more | - | 28 Feb 2024 | ||
placebo+mRNA-1010 (mRNA-1010 + Placebo) | jggkoiiida = cxmbmwlaar zdsefootce (wqxougoimb, hczgzvtiuy - hikqbncxjf) View more | ||||||
Not Applicable | - | 49 | (Recently transplanted patients (RTP)) | tzcfkphzyl(rgqfazxoyc) = hbfgguoviu vluzljchef (busohpwmnj ) View more | - | 08 Jun 2023 | |
(Long-term transplanted patients (LTTP)) | tzcfkphzyl(rgqfazxoyc) = gwccsogibw vluzljchef (busohpwmnj ) View more | ||||||
Not Applicable | 1,250 | BNT162b2(Pfizer-BioNTech) | bbdnentchd(ylwkimzqgj) = fgirfftgrq rbmwnxlzuq (mzpylvhfgd ) | Positive | 01 Jun 2023 | ||
(mRNA-1273(Moderna)) | bbdnentchd(ylwkimzqgj) = wqncqmkkpb rbmwnxlzuq (mzpylvhfgd ) |